Italy's Diagnostic Systems Tender Ends Without a Winner After No Bids Are Received

Standfirst:

Azienda Ulss 2 Marca Trevigiana has declared two lots in its laboratory diagnostics procurement unsuccessful after receiving no bids from suppliers. The cancelled competitions covered specialised diagnostic systems for tuberculosis culture testing and molecular detection, highlighting the procurement challenges facing highly specialised healthcare technologies in Italy.

Introduction

Modern laboratories depend on advanced diagnostic systems to detect infectious diseases quickly, but procurement does not always end with a signed contract. In Italy, two key lots in a major laboratory diagnostics tender closed without a winner after no suppliers submitted bids, forcing the contracting authority to reconsider how these specialised systems will be procured.

The failed procurement formed part of a much larger tender covering 23 categories of laboratory diagnostic systems for hospitals across the Treviso healthcare network. While most public attention focuses on contracts that are awarded, unsuccessful tenders can be equally significant. They often reveal gaps between public healthcare needs and supplier interest, particularly in highly specialised medical technologies where competition is limited.

Why This Contract Matters

Most procurement stories are about who won. This one is about who did not show up and that absence matters just as much.

A public hospital network planned to secure laboratory capacity to detect tuberculosis and carbapenem resistant infections for the next seven years. Instead, it now has two gaps in its diagnostic tender that will need to be resolved, either by retendering, adjusting the requirements or falling back on existing suppliers outside this competition.

For an industry watching how concentrated certain diagnostic equipment markets have become, a zero bid result on a properly structured, EU law compliant tender is a data point worth paying attention to.

Contract Timeline

• 1 October 2025, The estimated start date recorded for both lots, by which point the health authority had expected supply to begin.
• 6 July 2026, The result notice was dispatched for publication, confirming both lots closed without a winner.
• 8 July 2026, The notice was published in the Official Journal of the EU (OJ S 129/2026).

The gap between the planned start date and the publication of this result notice indicates that both lots remained unresolved for several months before the health authority formally closed them. The contracting authority has not disclosed a revised timeline or a retender date for either lot.

Contract Overview

The parent procedure is a large, 23 lot open tender run electronically by Azienda Ulss 2 Marca Trevigiana to secure "diagnostic systems" for its laboratory and microbiology services, structured as a service contract, meaning suppliers would provide equipment, software, reagents, technical support and staff training as one bundled package, rather than the health authority purchasing hardware outright.

The overall tender carries an estimated value of €215,480,016.60 excluding VAT across all 23 lots, running for a base period of 84 months (seven years) with a possible 24 month renewal. This notice reports results for two of those lots only: Lot 19 and Lot 20. Both were declared closed with no winner, because no tenders at all were submitted. Award status for the remaining 21 lots is not covered by this notice.

Key Contract Details

Detail	Lot 19	Lot 20
Lot title	Culture based diagnostic system for mycobacteria detection	Molecular diagnostic system for Mycobacterium tuberculosis complex and carbapenemase
Estimated value (excl. VAT)	€949,200.00	€621,500.00
Planned duration	84 months (plus renewal options)	84 months (plus renewal options)
Planned start date	1 October 2025	1 October 2025
Award criteria	Quality 70% / Cost 30%	Quality 70% / Cost 30%
Tenders received	0	0
Result	No winner, competition closed	No winner, competition closed
EU funding	Not financed with EU funds	Not financed with EU funds
GPA coverage	No	No
Framework agreement	None	None
Main CPV code	33124110 – Diagnostic systems	33124110 – Diagnostic systems
Legal basis	Directive 2014/24/EU	Directive 2014/24/EU
Review body	Regional Administrative Court for Veneto (TAR Veneto)	Regional Administrative Court for Veneto (TAR Veneto)

Project Scope

Lot 19 sought a culture based diagnostic system to detect mycobacteria, the family of bacteria that includes the species responsible for tuberculosis, across different types of biological samples taken from patients. Culture testing remains a reference method in TB diagnosis: it grows the bacteria from a sample over time in a controlled environment, allowing laboratories to confirm infection and test which drugs the specific strain will respond to.

Lot 20 targeted a molecular biology diagnostic system, a faster genetic testing method that reads a pathogen's DNA directly rather than waiting for it to grow in culture, aimed specifically at detecting Mycobacterium tuberculosis complex (the group of bacteria that cause TB) and carbapenemase genes, the genetic trait that allows certain bacteria to resist carbapenems, a class of antibiotics doctors typically reserve for serious, hard to treat infections.

Both lots were structured as full service contracts: the winning supplier would have provided not just the analytical equipment but management software, reagents and consumables, "full risk" technical assistance (meaning the supplier bears responsibility for keeping the equipment running), staff training and two way data interfacing with the health authority's central laboratory information system, referred to in the notice as the BASE Middleware.

About the Contracting Authority

Azienda Ulss 2 Marca Trevigiana is the public health authority responsible for health services across the Treviso area of the Veneto region. It is classified in the notice as a body governed by public law with health as its main activity, the standard designation for an Italian regional health trust operating hospitals and laboratory services on behalf of the public system.

The authority ran this tender electronically through the Veneto region's SINTEL procurement platform, operated by ARIA S.p.A., the regional central purchasing agency. Its role here is straightforward: it structured the 23 lot tender, defined the technical requirements for each lot and evaluated whatever bids came in, in the case of Lots 19 and 20, none did.

About the Organisations Involved

Azienda Ulss 2 Marca Trevigiana, Buyer

Based in Treviso, this is the contracting authority that designed and ran the tender. It set the requirements for both diagnostic systems, structured the contracts as 84 month service agreements and is now responsible for deciding what happens next, whether that means retendering the two lots, amending the specification or securing the equipment through another route.

Tribunale Amministrativo Regionale per il Veneto (TAR Veneto), Review Organisation

This is the Regional Administrative Court for Veneto, based in Venice, the body suppliers could have turned to if they believed either competition was run unfairly. Because no tenders were submitted for either lot, its role in this specific result is procedural: it exists as the designated review authority, named in the notice, but there is no indication in the notice that any review was triggered.

There are no winning suppliers to report for either lot in this notice. Both competitions closed without an award, so no company holds a contract, framework position or subcontracting role arising from Lots 19 or 20.

Procurement Analysis

The health authority ran this as an open electronic procedure, meaning any qualified operator could submit a bid through the SINTEL platform without a pre qualification stage. That is the standard route for tenders of this size and complexity and nothing in the notice suggests a procedural flaw in how the competition was structured.

Award criteria combined quality (70%) and cost (30%), a heavily quality weighted formula typical of specialised medical laboratory equipment, where the health authority wanted technical performance to matter roughly twice as much as price. That weighting usually signals a buyer prioritising accuracy, reliability and service quality over the cheapest possible bid, the opposite of a race to the bottom price tender.

Despite that buyer friendly structure, zero tenders were received for either lot. Under EU procurement rules, a result of "no tenders, requests to participate or projects were received" is a recognised, formally reportable outcome and it closes the competition rather than triggering an automatic retender, the health authority must actively decide its next step.

Neither lot was financed by EU funds and neither was covered by the WTO Government Procurement Agreement, unlike some larger centralised health tenders. Both were structured with a quinto d'obbligo clause, a standard feature in Italian public contracts allowing the buyer to increase or decrease contract volume by up to one fifth during execution without the supplier being able to walk away, plus options to extend the contract by up to 24 months and potentially a further 6 months beyond that.

Additional Procurement Facts

The health authority's additional notes in the tender documentation flagged that it reserved the right to suspend, modify, revoke or partially cancel the procedure at any point, including if a regional or national central purchasing body such as CONSIP activated a framework covering the same product category during the tender's lifetime, a common safeguard clause in Italian regional health procurement to avoid overlapping national and local contracts.

The notice also confirms the tender used "inversione procedimentale" under Article 107(3) of Italy's Public Contracts Code, a procedural technique where technical and economic bids are evaluated before administrative eligibility documents are checked, intended to speed up evaluation. The project's designated responsible officer is named as the director of the health authority's procurement and supply unit and the eventual contract was set to exclude an arbitration clause, meaning any dispute would go through ordinary administrative courts rather than arbitration.

Market & Industry Perspective

Zero bid outcomes are unusual but not unheard of in specialised diagnostics procurement and they tend to cluster around product categories where very few manufacturers worldwide make equipment that matches the exact technical specification a health authority has written into its tender.

Tuberculosis culture systems and molecular platforms for detecting M. tuberculosis and carbapenemase genes sit in a genuinely narrow segment of the in vitro diagnostics market, dominated globally by a small number of established manufacturers. If a hospital's existing laboratory workflow, software interfacing requirements or accreditation history already ties it closely to one incumbent system, competitors may judge the cost of adapting their platform to match the specification, for a contract of this size, as commercially unattractive, even when the buyer is offering a seven year, quality weighted contract.

It is also possible that suppliers judged the annual value of each lot, averaging roughly €135,600 a year for Lot 19 and €88,800 a year for Lot 20 across the 84 month term, too small relative to the cost of installing dedicated laboratory hardware and committing to "full risk" maintenance for seven years. The notice does not disclose supplier feedback or bidder withdrawal reasons, so these remain plausible market explanations rather than confirmed facts.

Economic Significance

On its own, this result is a rounding error inside a €215 million tender. But it illustrates a structural risk in centralising diagnostic procurement into large, multi lot competitions: if even one or two specialised lots are written too narrowly or pitched at a scale too small to interest global manufacturers, entire clinical capabilities can fall through the cracks of an otherwise successful procurement exercise.

For public health budgeting, an unresolved lot is not a saved cost. It typically means the health authority must fall back on existing, potentially less favourable arrangements or delay upgrading its TB and antimicrobial resistance testing capacity while it re runs the competition, a cost measured in clinical capability and time rather than euros.

Future Procurement Opportunities

The health authority will most likely need to retender Lots 19 and 20, either unchanged or with revised technical specifications designed to widen the pool of eligible suppliers. Manufacturers of TB diagnostic systems and molecular pathogen detection platforms that did not bid this time have a clear opening to engage directly with Azienda Ulss 2 Marca Trevigiana before any retender is published, to flag specification issues that may have deterred them.

The remaining 21 lots within the same ID 3677 programme, covering other categories of laboratory diagnostic systems, are not addressed in this notice and may represent separate live opportunities, already awarded, still pending or facing the same zero bid outcome. Suppliers active in Italian regional health diagnostics should track the parent procedure directly for the status of those other lots.

Opportunities for Suppliers

• A validated gap now exists. Two specific, publicly documented diagnostic requirements have gone unmet; any manufacturer capable of meeting the technical specification has a rare, low competition opening if a retender follows.
• Specification feedback is valuable currency. Suppliers who chose not to bid can proactively contact the health authority to explain why, narrow technical wording, interfacing requirements or contract scale, and potentially shape a retender that they can then win.
• Quality weighted criteria favour differentiated technology. A 70/30 quality to cost split rewards suppliers who can demonstrate superior diagnostic accuracy and service reliability, not simply the lowest price, which should appeal to specialist rather than generalist diagnostics firms.

What Businesses Should Watch

Watch for a retender notice from Azienda Ulss 2 Marca Trevigiana covering Lots 19 and 20 and note whether the specification, contract scale or duration changes from this attempt.

Watch how the health authority handles interim diagnostic capacity for TB and carbapenemase detection while these two lots remain unresolved, any short term or emergency procurement route taken in the meantime may itself be a public tender worth tracking.

Watch the outcome of the other 21 lots in the same ID 3677 procedure; a pattern of multiple zero bid results across the programme would be a stronger signal about specification design than a single isolated case.

Italytenders.com Procurement Intelligence

This notice is a useful reminder that procurement success is not just about running a compliant process, it is about designing lots that the market can actually answer. A health authority can follow EU procurement law precisely, weight its criteria toward quality and still end up with an empty result if the specification only matches equipment from manufacturers who, for commercial reasons of their own, choose not to compete for a contract of this particular size and shape.

The likely explanation here sits at the intersection of a highly concentrated global supplier base for TB and molecular pathogen diagnostics and a contract scale that may not have justified the investment those suppliers would need to make to bid. That combination is worth watching across Europe as more regional health systems bundle specialised laboratory categories into large multi lot tenders: bundling brings efficiency for the buyer, but it can also mean that one poorly calibrated lot, buried among twenty others, quietly fails while the rest of the tender proceeds normally.

For suppliers, the lesson cuts both ways. Manufacturers who sat this one out have a genuine chance to influence the next attempt. And competitors who could have bid but did not may want to ask themselves whether they are missing a defensible slice of Italy's regional health diagnostics market simply because nobody engaged with the buyer before the tender closed.

Supplier Takeaways

• Contact Azienda Ulss 2 Marca Trevigiana's procurement office directly if your organisation makes TB culture or molecular diagnostic systems, even before a retender is published, to discuss specification design.
• Monitor the parent tender (ID 3677) for the outcome of its remaining 21 lots, which may reveal whether zero bid results are isolated or systemic across this procurement.
• Reassess whether smaller scale, single authority diagnostic contracts in Italy's regional health system are being under served by global manufacturers focused on larger national frameworks, this may be a genuine market gap rather than a one off.
• Prepare technical documentation showing full risk service capability and BASE Middleware interfacing compatibility in advance, since both were explicit requirements in this tender and are likely to reappear in any retender.

Key Takeaways

• Two lots within a 23 lot, €215.5 million Italian regional health tender, covering tuberculosis culture testing and molecular detection of TB and antibiotic resistant bacteria, closed with zero bids received.
• Combined, the two lots were worth just under €1.6 million over a planned 84 month contract term.
• Award criteria were heavily weighted toward quality (70%) over cost (30%), yet still attracted no supplier interest.
• No EU funding or GPA coverage applied to either lot and no framework agreement was involved.
• The health authority, Azienda Ulss 2 Marca Trevigiana, must now decide whether to retender, revise the specification or pursue an alternative procurement route for both diagnostic categories.

Conclusion

Not every procurement story ends with a winner and this one is a reminder that empty competitions carry their own lessons. A specialised, quality focused tender for tuberculosis and antimicrobial resistance diagnostics found no takers in northern Italy, leaving a regional health authority with a gap in its laboratory capability and a decision to make. For suppliers paying attention, that gap is now public, documented and open for the taking.

Frequently Asked Questions

Q1. What happens when a public tender lot receives zero bids?

Under EU procurement rules, this is a recognised outcome: the competition for that lot is formally closed with no winner and the contracting authority must then decide whether to retender, amend the specification or pursue the requirement through another procurement route.

Q2. What is a culture based diagnostic system for mycobacteria?

It is laboratory equipment used to grow bacteria from a patient sample under controlled conditions, allowing technicians to confirm a tuberculosis infection and test which antibiotics the specific bacterial strain will respond to.

Q3. What is carbapenemase and why does it matter?

Carbapenemase is a gene some bacteria carry that lets them resist carbapenems, a class of antibiotics doctors typically reserve for severe infections that do not respond to other drugs. Detecting it quickly helps hospitals control the spread of hard to treat, drug resistant infections.

Q4. Why might a well structured tender still attract no bids?

Common reasons include a technical specification that only a small number of global manufacturers can meet, a contract value too small to justify the investment a new supplier would need to make or existing supplier relationships that make switching costly for both buyer and market.

Q5. Does this affect the rest of the 23 lot tender?

This notice only reports results for Lots 19 and 20. The award status of the other 21 lots in the same procedure is not covered here.

Q6. Was this contract financed by EU funds?

No. Both lots were confirmed as not financed with EU funds and neither was covered by the WTO Government Procurement Agreement.

Q7. What is the BASE Middleware mentioned in the tender?

It is described in the notice as the central software system used to interface diagnostic equipment with the health authority's laboratory data systems. The contracting authority has not disclosed further technical detail about this system.

Source: EU Official Journal, Contract Award Notice 470245 2026, OJ S 129/2026, published 8 July 2026. Contracting authority: Azienda Ulss 2 Marca Trevigiana.